Fan Qing Meng

Shenzhen Investment Holdings Co., Ltd. operates as a state-owned asset management company. Its business activities include management of properties, capital operation, investment and financing, transportation logistics, manufacturing and trading, and modern service industries. The company was founded on October 13, 2004 and is headquartered in Shenzhen, China.

Hangzhou Sciwind Biosciences Co., Ltd. is a biopharmaceutical company based in Hangzhou, China. The Chinese company's product pipeline includes potentially first-in-class and drug candidates, such as the long-acting glp-1 peptide analog ecnoglutide (phase 3), oral glp-1 peptide analog xw004 (phase 1), and oral small molecule glp-1 receptor agonist xw014 (phase 1). Sciwind has developed multiple proprietary technologies, including oral peptide and inhaled protein therapeutic delivery platforms, and identified a series of drug candidates based on these core platform technologies. The company was founded in 2017 by Hai Pan, who has been the CEO since 2017.

Chiral Quest (Suzhou) Co. Ltd. provides drug discovery services. It focuses on the development and manufacture of chiral catalysts, development of synthetic processes, and a technology applications platform. Its products include a, b, and Cyclicb-amino acids; b-hydroxy acids; chiral amines, alcohols, amino alcohols, and pyrrolidines; succinates; and achiral compounds, a-hydroxy acids, and APIs and intermediates. Chiral Quest has one manufacturing site in Jiangxi province, and three overseas offices in USA, Europe & India respectively. The company was founded by Xumu Zhang in 2000 and is headquartered in Suzhou, China.